H.R. 2547: Surrogate Endpoint Improvement and Utilization Act of 2015

To amend the Federal Food, Drug, and Cosmetic Act to provide for the development of accelerated approval development plans for investigational drugs and biological products.

The bill’s titles are written by its sponsor.

What you can do



May 21, 2015


Referred to Committee on May 21, 2015

This bill was assigned to a congressional committee on May 21, 2015, which will consider it before possibly sending it on to the House or Senate as a whole.


Cathy McMorris Rodgers

Representative for Washington's 5th congressional district



Read Text »
Last Updated: May 21, 2015
Length: 4 pages


1% chance of being enacted according to PredictGov (details)


May 21, 2015

This is the first step in the legislative process.

Reported by Committee

Passed House

Passed Senate

Signed by the President

H.R. 2547 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 2547 — 114th Congress: Surrogate Endpoint Improvement and Utilization Act of 2015.” www.GovTrack.us. 2015. October 27, 2016 <https://www.govtrack.us/congress/bills/114/hr2547>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.